View ValuationUFP Technologies 향후 성장Future 기준 점검 1/6UFP Technologies은 연간 수입과 매출이 각각 12.5%와 6.2% 증가할 것으로 예상되고 EPS는 연간 10.6%만큼 증가할 것으로 예상됩니다.핵심 정보12.5%이익 성장률10.58%EPS 성장률Medical Equipment 이익 성장13.3%매출 성장률6.2%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트11 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • 9hUFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic IndexUFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic Index공시 • Jun 11Ufp Technologies, Inc. Announces Appointment of Mitchell C. Rock to the Board, Effective June 4, 2026UFP Technologies, Inc. announced that on June 4, 2026, the Board appointed Mitchell C. Rock to fill the vacancy on the Board created by such increase in Board size. Mr. Rock will serve on the Board until the Company’s next annual stockholder meeting or until his successor has been duly appointed and qualified or until his earlier death, resignation, retirement, disqualification, removal from office or other cause.공시 • Jun 05UFP Technologies, Inc. Announces Appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, Effective June 4, 2026UFP Technologies, Inc. announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026. Stafford succeeded Chris Litterio, who retired after having played a pivotal role in the company’s growth. Stafford brought nearly three decades of experience as a senior legal and human resources leader at high-growth, publicly traded companies, leading Legal and Human Resources and overseeing M&A as well as helping guide corporate growth through both acquisition execution and organizational development. Most recently, Stafford served as Executive Vice President, Chief Legal Officer, Corporate Secretary, and head of Mergers & Acquisitions at Littelfuse, Inc. He joined Littelfuse in 2007 as General Counsel and Vice President of Human Resources, later advancing to Senior Vice President and Chief Legal and Human Resources from 2014 to 2021. In 2021, he was named Executive Vice President, Mergers & Acquisitions and Chief Legal Officer, where he led the company’s acquisition strategy. Prior to Littelfuse, Stafford held senior legal and operational roles at Tyco International Ltd., including Vice President & General Counsel for Tyco Engineered Products & Services and Vice President of China Operations for the segment. He began his legal career as an associate at Sulloway & Hollis, a New Hampshire law firm. Stafford earned a Bachelor of Arts in History and German from Bowdoin College and a Juris Doctor from the University of Maine School of Law.공시 • May 27UFP Technologies, Inc. Announces Retirement of Christopher P. Litterio from General Counsel, Secretary, and Senior Vice President of Human ResourcesUFP Technologies, Inc. announced that on May 19, 2026, Christopher P. Litterio, General Counsel, Secretary, and Senior Vice President of Human Resources, informed the company that he planned to retire from the company after a period of transition.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director John Hassett was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • May 20Lead Independent Director recently sold €542k worth of stockOn the 12th of May, Daniel Croteau sold around 3k shares on-market at roughly €189 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.4m more than they bought in the last 12 months.공시 • May 04UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026.공시 • May 01UFP Technologies, Inc. to Report Q1, 2026 Results on May 04, 2026UFP Technologies, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 04, 2026공시 • Feb 20UFP Technologies, Inc. to Report Q4, 2025 Results on Feb 24, 2026UFP Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026공시 • Dec 03+ 1 more updateUFP Technologies, Inc. Technologies Announces Board ChangesUFP Technologies, Inc. announced that R. Jeffrey Bailly will retire as CEO at the Company’s next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will join the Company’s Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the following year. Mr. Bailly intends to remain on the Board of Directors of the Company (the Board"). Mr. Rock, age 58, initially joined the Company in 1991 and served as Director, Sales and Marketing of what was the Company's Moulded Fibre division. From May 1999 through October 2000, Mr. Rock left the Company to serve as Vice President, Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined the Company in April 2001 as Vice President, Sales and Marketing of the Moulded Fibre division and served as the Company's Vice President of Sales and Marketing from May 2002 to June 2014. From June 2014 to June 2021, Mr. Rock served as the Company's Senior Vice President of Sales and Marketing, and from January 1, 2020 to June 2021, Mr. Rock also served as General Manager, Medical. From June 2021, Mr. Rock served as President, UFP MedTech. Since February 2024, Mr. Rock has served as President of the Company. Since 2016, Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.공시 • Oct 29UFP Technologies, Inc. to Report Q3, 2025 Results on Nov 03, 2025UFP Technologies, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025공시 • Jul 30UFP Technologies, Inc. to Report Q2, 2025 Results on Aug 04, 2025UFP Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025공시 • Jul 17UFP Technologies, Inc. (NasdaqCM:UFPT) acquired Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into securities purchase agreement to acquire Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million on July 7, 2025. A cash consideration of $4.5 million will be paid by UFP Technologies, Inc. towards common equity of Techno Plastics Industries, Inc. The transaction were financed with available cash and borrowings under UFP’s existing credit facility. For the period ending December 31, 2024, Techno Plastics Industries, Inc. reported total revenue of approximately $10 million and EBITDA of $1 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Techno Plastics Industries, Inc. from a group of shareholders on July 17, 2025.공시 • May 01UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025.공시 • Apr 30UFP Technologies, Inc. to Report Q1, 2025 Results on May 06, 2025UFP Technologies, Inc. announced that they will report Q1, 2025 results Pre-Market on May 06, 2025공시 • Feb 19UFP Technologies, Inc. to Report Q4, 2024 Results on Feb 25, 2025UFP Technologies, Inc. announced that they will report Q4, 2024 results on Feb 25, 2025Recent Insider Transactions • Nov 14CEO & Chairman recently sold €8.3m worth of stockOn the 11th of November, R. Bailly sold around 25k shares on-market at roughly €327 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €13m. R. has been a net seller over the last 12 months, reducing personal holdings by €49m.Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 27%After last week's 27% share price gain to €321, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 435% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €144 per share.Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: US$2.13 (vs US$1.53 in 3Q 2023)Third quarter 2024 results: EPS: US$2.13 (up from US$1.53 in 3Q 2023). Revenue: US$145.2m (up 44% from 3Q 2023). Net income: US$16.4m (up 40% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.공시 • Aug 27UFP Technologies, Inc. (NasdaqCM:UFPT) acquired AQF Ltd for €43 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into a share purchase agreement to acquire AQF Ltd for €43 million on August 23, 2024. The shares were acquired for an aggregate purchase price of €43.0 million in cash. The aggregate purchase price at closing was approximately 12.3 times AQF Medical’s adjusted net income before interest, taxes, depreciation and amortization for the 12-month period ended June 30, 2024. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of AQF Ltd on August 26, 2024.Recent Insider Transactions • Aug 08CFO, Senior VP & Treasurer recently sold €3.6m worth of stockOn the 6th of August, Ronald Lataille sold around 13k shares on-market at roughly €278 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ronald has been a net seller over the last 12 months, reducing personal holdings by €3.7m.Reported Earnings • Aug 01Second quarter 2024 earnings released: EPS: US$1.77 (vs US$1.56 in 2Q 2023)Second quarter 2024 results: EPS: US$1.77 (up from US$1.56 in 2Q 2023). Revenue: US$110.2m (up 10% from 2Q 2023). Net income: US$13.6m (up 14% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 73% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jul 17+ 1 more updateUFP Technologies, Inc. (NasdaqCM:UFPT) acquired Marble Medical Inc. for $5 million from Joseph J. Audie.UFP Technologies, Inc. (NasdaqCM:UFPT) signed a Stock Purchase Agreement to acquire Marble Medical Inc. for $5 million from Joseph J. Audie on June 24, 2024. The Marble shares were acquired for an aggregate purchase price of $4.5 million in cash plus up to an additional $0.5 million based upon the achievement of sales targets of Marble for each of the 12-month periods ended December 31, 2024 and 2025. In a related transaction UFP Technologies, Inc. acquired Welch Fluorocarbon. The aggregate purchase price at closing was approximately 4.5 times the Marble adjusted EBITDA. Marble Medical Inc. has annual sales of approximately $5 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Marble Medical Inc. for $5 million from Joseph J. Audie on July 16, 2024.Reported Earnings • May 02First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.28 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.28 in 1Q 2023). Revenue: US$105.0m (up 7.4% from 1Q 2023). Net income: US$12.7m (up 30% from 1Q 2023). Profit margin: 12% (up from 10.0% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.공시 • Apr 29UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the seven directors identified as standing for election in the accompanying proxy statement, each to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected; to vote on a non binding advisory resolution to approve the compensation of named executive officers; to ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ended December 31, 2024; and to transact such other business as may properly come before the 2024 Annual Meeting of Stockholders, and at any adjournment or postponement thereof.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €206, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 390% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €294 per share.Recent Insider Transactions • Mar 03CEO & Chairman recently sold €5.2m worth of stockOn the 23rd of February, R. Bailly sold around 27k shares on-market at roughly €194 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €19m.Reported Earnings • Feb 22Full year 2023 earnings released: EPS: US$5.89 (vs US$5.53 in FY 2022)Full year 2023 results: EPS: US$5.89 (up from US$5.53 in FY 2022). Revenue: US$400.1m (up 13% from FY 2022). Net income: US$44.9m (up 7.5% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany.공시 • Feb 06UFP Technologies, Inc. Announces Executive ChangesUFP Technologies, Inc. announced the appointment of Mitchell Rock as President of the Company. Rock has been serving as President of the Company’s MedTech business. R. Jeffrey Bailly will continue in his capacity as Chairman and Chief Executive Officer.Recent Insider Transactions • Dec 18Chairman of the Board of Directors recently sold €3.3m worth of stockOn the 14th of December, R. Bailly sold around 20k shares on-market at roughly €164 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €11m.Recent Insider Transactions • Dec 06Chairman of the Board of Directors recently sold €1.2m worth of stockOn the 30th of November, R. Bailly sold around 7k shares on-market at roughly €158 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.9m. R. has been a net seller over the last 12 months, reducing personal holdings by €7.3m.Recent Insider Transactions • Nov 27Chairman of the Board of Directors recently sold €208k worth of stockOn the 21st of November, R. Bailly sold around 1k shares on-market at roughly €160 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.7m. R. has been a net seller over the last 12 months, reducing personal holdings by €3.2m.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$1.53 (vs US$2.58 in 3Q 2022)Third quarter 2023 results: EPS: US$1.53 (down from US$2.58 in 3Q 2022). Revenue: US$100.8m (up 3.9% from 3Q 2022). Net income: US$11.7m (down 40% from 3Q 2022). Profit margin: 12% (down from 20% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.Recent Insider Transactions • Sep 03Chairman of the Board of Directors recently sold €2.7m worth of stockOn the 31st of August, R. Bailly sold around 17k shares on-market at roughly €163 per share. This transaction amounted to 4.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €12m.Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$1.56 (vs US$1.18 in 2Q 2022)Second quarter 2023 results: EPS: US$1.56 (up from US$1.18 in 2Q 2022). Revenue: US$100.0m (up 6.0% from 2Q 2022). Net income: US$11.9m (up 33% from 2Q 2022). Profit margin: 12% (up from 9.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany.Recent Insider Transactions • May 10Independent Director recently sold €3.4m worth of stockOn the 8th of May, Thomas Oberdorf sold around 27k shares on-market at roughly €129 per share. This transaction amounted to 91% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €16m more than they bought in the last 12 months.Board Change • Apr 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Cynthia Feldmann was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €120, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total returns to shareholders of 102% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €85.63 per share.Reported Earnings • Mar 12Full year 2022 earnings released: EPS: US$5.53 (vs US$2.11 in FY 2021)Full year 2022 results: EPS: US$5.53 (up from US$2.11 in FY 2021). Revenue: US$353.8m (up 72% from FY 2021). Net income: US$41.8m (up 163% from FY 2021). Profit margin: 12% (up from 7.7% in FY 2021). Revenue is forecast to grow 4.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.이익 및 매출 성장 예측DB:UFP - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202872598N/AN/A112/31/20276798595100412/31/202664075708643/31/2026609696981N/A12/31/2025603687992N/A9/30/2025598678799N/A6/30/2025589677383N/A3/31/2025548635970N/A12/31/2024504595767N/A9/30/2024462544555N/A6/30/2024417504353N/A3/31/2024407484050N/A12/31/2023400453141N/A9/30/2023390423647N/A6/30/2023386501828N/A3/31/202338047923N/A12/31/202235442418N/A9/30/202231937-110N/A6/30/202227321-64N/A3/31/20222291718N/A12/31/202120616914N/A9/30/2021195171622N/A6/30/2021188161924N/A3/31/2021180141924N/A12/31/2020179132125N/A9/30/2020184152126N/A6/30/2020191182430N/A3/31/2020199202732N/A12/31/201919820N/A31N/A9/30/201919918N/A30N/A6/30/201919717N/A26N/A3/31/201919516N/A27N/A12/31/201819014N/A21N/A9/30/201817713N/A18N/A6/30/201816510N/A17N/A3/31/20181549N/A11N/A12/31/20171489N/A17N/A9/30/20171478N/A16N/A6/30/20171499N/A16N/A3/31/20171499N/A16N/A12/31/20161468N/A9N/A9/30/20161448N/A10N/A6/30/20161417N/A9N/A3/31/20161397N/A12N/A12/31/20151398N/A13N/A9/30/20151407N/A14N/A6/30/20151418N/A15N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: UFP 의 연간 예상 수익 증가율(12.5%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: UFP 의 연간 수익(12.5%)이 German 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: UFP 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: UFP 의 수익(연간 6.2%)이 German 시장(연간 6.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: UFP 의 수익(연간 6.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: UFP의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/29 19:07종가2026/06/26 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스UFP Technologies, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jonathan TanwantengCJS Securities, Inc.Justin AgesCJS Securities, Inc.Brett FishbinKeyBanc Capital Markets Inc.4명의 분석가 더 보기
공시 • 9hUFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic IndexUFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic Index
공시 • Jun 11Ufp Technologies, Inc. Announces Appointment of Mitchell C. Rock to the Board, Effective June 4, 2026UFP Technologies, Inc. announced that on June 4, 2026, the Board appointed Mitchell C. Rock to fill the vacancy on the Board created by such increase in Board size. Mr. Rock will serve on the Board until the Company’s next annual stockholder meeting or until his successor has been duly appointed and qualified or until his earlier death, resignation, retirement, disqualification, removal from office or other cause.
공시 • Jun 05UFP Technologies, Inc. Announces Appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, Effective June 4, 2026UFP Technologies, Inc. announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026. Stafford succeeded Chris Litterio, who retired after having played a pivotal role in the company’s growth. Stafford brought nearly three decades of experience as a senior legal and human resources leader at high-growth, publicly traded companies, leading Legal and Human Resources and overseeing M&A as well as helping guide corporate growth through both acquisition execution and organizational development. Most recently, Stafford served as Executive Vice President, Chief Legal Officer, Corporate Secretary, and head of Mergers & Acquisitions at Littelfuse, Inc. He joined Littelfuse in 2007 as General Counsel and Vice President of Human Resources, later advancing to Senior Vice President and Chief Legal and Human Resources from 2014 to 2021. In 2021, he was named Executive Vice President, Mergers & Acquisitions and Chief Legal Officer, where he led the company’s acquisition strategy. Prior to Littelfuse, Stafford held senior legal and operational roles at Tyco International Ltd., including Vice President & General Counsel for Tyco Engineered Products & Services and Vice President of China Operations for the segment. He began his legal career as an associate at Sulloway & Hollis, a New Hampshire law firm. Stafford earned a Bachelor of Arts in History and German from Bowdoin College and a Juris Doctor from the University of Maine School of Law.
공시 • May 27UFP Technologies, Inc. Announces Retirement of Christopher P. Litterio from General Counsel, Secretary, and Senior Vice President of Human ResourcesUFP Technologies, Inc. announced that on May 19, 2026, Christopher P. Litterio, General Counsel, Secretary, and Senior Vice President of Human Resources, informed the company that he planned to retire from the company after a period of transition.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director John Hassett was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • May 20Lead Independent Director recently sold €542k worth of stockOn the 12th of May, Daniel Croteau sold around 3k shares on-market at roughly €189 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.4m more than they bought in the last 12 months.
공시 • May 04UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026.
공시 • May 01UFP Technologies, Inc. to Report Q1, 2026 Results on May 04, 2026UFP Technologies, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 04, 2026
공시 • Feb 20UFP Technologies, Inc. to Report Q4, 2025 Results on Feb 24, 2026UFP Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026
공시 • Dec 03+ 1 more updateUFP Technologies, Inc. Technologies Announces Board ChangesUFP Technologies, Inc. announced that R. Jeffrey Bailly will retire as CEO at the Company’s next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will join the Company’s Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the following year. Mr. Bailly intends to remain on the Board of Directors of the Company (the Board"). Mr. Rock, age 58, initially joined the Company in 1991 and served as Director, Sales and Marketing of what was the Company's Moulded Fibre division. From May 1999 through October 2000, Mr. Rock left the Company to serve as Vice President, Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined the Company in April 2001 as Vice President, Sales and Marketing of the Moulded Fibre division and served as the Company's Vice President of Sales and Marketing from May 2002 to June 2014. From June 2014 to June 2021, Mr. Rock served as the Company's Senior Vice President of Sales and Marketing, and from January 1, 2020 to June 2021, Mr. Rock also served as General Manager, Medical. From June 2021, Mr. Rock served as President, UFP MedTech. Since February 2024, Mr. Rock has served as President of the Company. Since 2016, Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.
공시 • Oct 29UFP Technologies, Inc. to Report Q3, 2025 Results on Nov 03, 2025UFP Technologies, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025
공시 • Jul 30UFP Technologies, Inc. to Report Q2, 2025 Results on Aug 04, 2025UFP Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025
공시 • Jul 17UFP Technologies, Inc. (NasdaqCM:UFPT) acquired Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into securities purchase agreement to acquire Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million on July 7, 2025. A cash consideration of $4.5 million will be paid by UFP Technologies, Inc. towards common equity of Techno Plastics Industries, Inc. The transaction were financed with available cash and borrowings under UFP’s existing credit facility. For the period ending December 31, 2024, Techno Plastics Industries, Inc. reported total revenue of approximately $10 million and EBITDA of $1 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Techno Plastics Industries, Inc. from a group of shareholders on July 17, 2025.
공시 • May 01UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025.
공시 • Apr 30UFP Technologies, Inc. to Report Q1, 2025 Results on May 06, 2025UFP Technologies, Inc. announced that they will report Q1, 2025 results Pre-Market on May 06, 2025
공시 • Feb 19UFP Technologies, Inc. to Report Q4, 2024 Results on Feb 25, 2025UFP Technologies, Inc. announced that they will report Q4, 2024 results on Feb 25, 2025
Recent Insider Transactions • Nov 14CEO & Chairman recently sold €8.3m worth of stockOn the 11th of November, R. Bailly sold around 25k shares on-market at roughly €327 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €13m. R. has been a net seller over the last 12 months, reducing personal holdings by €49m.
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 27%After last week's 27% share price gain to €321, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 435% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €144 per share.
Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: US$2.13 (vs US$1.53 in 3Q 2023)Third quarter 2024 results: EPS: US$2.13 (up from US$1.53 in 3Q 2023). Revenue: US$145.2m (up 44% from 3Q 2023). Net income: US$16.4m (up 40% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Aug 27UFP Technologies, Inc. (NasdaqCM:UFPT) acquired AQF Ltd for €43 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into a share purchase agreement to acquire AQF Ltd for €43 million on August 23, 2024. The shares were acquired for an aggregate purchase price of €43.0 million in cash. The aggregate purchase price at closing was approximately 12.3 times AQF Medical’s adjusted net income before interest, taxes, depreciation and amortization for the 12-month period ended June 30, 2024. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of AQF Ltd on August 26, 2024.
Recent Insider Transactions • Aug 08CFO, Senior VP & Treasurer recently sold €3.6m worth of stockOn the 6th of August, Ronald Lataille sold around 13k shares on-market at roughly €278 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ronald has been a net seller over the last 12 months, reducing personal holdings by €3.7m.
Reported Earnings • Aug 01Second quarter 2024 earnings released: EPS: US$1.77 (vs US$1.56 in 2Q 2023)Second quarter 2024 results: EPS: US$1.77 (up from US$1.56 in 2Q 2023). Revenue: US$110.2m (up 10% from 2Q 2023). Net income: US$13.6m (up 14% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 73% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jul 17+ 1 more updateUFP Technologies, Inc. (NasdaqCM:UFPT) acquired Marble Medical Inc. for $5 million from Joseph J. Audie.UFP Technologies, Inc. (NasdaqCM:UFPT) signed a Stock Purchase Agreement to acquire Marble Medical Inc. for $5 million from Joseph J. Audie on June 24, 2024. The Marble shares were acquired for an aggregate purchase price of $4.5 million in cash plus up to an additional $0.5 million based upon the achievement of sales targets of Marble for each of the 12-month periods ended December 31, 2024 and 2025. In a related transaction UFP Technologies, Inc. acquired Welch Fluorocarbon. The aggregate purchase price at closing was approximately 4.5 times the Marble adjusted EBITDA. Marble Medical Inc. has annual sales of approximately $5 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Marble Medical Inc. for $5 million from Joseph J. Audie on July 16, 2024.
Reported Earnings • May 02First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.28 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.28 in 1Q 2023). Revenue: US$105.0m (up 7.4% from 1Q 2023). Net income: US$12.7m (up 30% from 1Q 2023). Profit margin: 12% (up from 10.0% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Apr 29UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the seven directors identified as standing for election in the accompanying proxy statement, each to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected; to vote on a non binding advisory resolution to approve the compensation of named executive officers; to ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ended December 31, 2024; and to transact such other business as may properly come before the 2024 Annual Meeting of Stockholders, and at any adjournment or postponement thereof.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €206, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 390% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €294 per share.
Recent Insider Transactions • Mar 03CEO & Chairman recently sold €5.2m worth of stockOn the 23rd of February, R. Bailly sold around 27k shares on-market at roughly €194 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €19m.
Reported Earnings • Feb 22Full year 2023 earnings released: EPS: US$5.89 (vs US$5.53 in FY 2022)Full year 2023 results: EPS: US$5.89 (up from US$5.53 in FY 2022). Revenue: US$400.1m (up 13% from FY 2022). Net income: US$44.9m (up 7.5% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany.
공시 • Feb 06UFP Technologies, Inc. Announces Executive ChangesUFP Technologies, Inc. announced the appointment of Mitchell Rock as President of the Company. Rock has been serving as President of the Company’s MedTech business. R. Jeffrey Bailly will continue in his capacity as Chairman and Chief Executive Officer.
Recent Insider Transactions • Dec 18Chairman of the Board of Directors recently sold €3.3m worth of stockOn the 14th of December, R. Bailly sold around 20k shares on-market at roughly €164 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €11m.
Recent Insider Transactions • Dec 06Chairman of the Board of Directors recently sold €1.2m worth of stockOn the 30th of November, R. Bailly sold around 7k shares on-market at roughly €158 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.9m. R. has been a net seller over the last 12 months, reducing personal holdings by €7.3m.
Recent Insider Transactions • Nov 27Chairman of the Board of Directors recently sold €208k worth of stockOn the 21st of November, R. Bailly sold around 1k shares on-market at roughly €160 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.7m. R. has been a net seller over the last 12 months, reducing personal holdings by €3.2m.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$1.53 (vs US$2.58 in 3Q 2022)Third quarter 2023 results: EPS: US$1.53 (down from US$2.58 in 3Q 2022). Revenue: US$100.8m (up 3.9% from 3Q 2022). Net income: US$11.7m (down 40% from 3Q 2022). Profit margin: 12% (down from 20% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.
Recent Insider Transactions • Sep 03Chairman of the Board of Directors recently sold €2.7m worth of stockOn the 31st of August, R. Bailly sold around 17k shares on-market at roughly €163 per share. This transaction amounted to 4.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €12m.
Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$1.56 (vs US$1.18 in 2Q 2022)Second quarter 2023 results: EPS: US$1.56 (up from US$1.18 in 2Q 2022). Revenue: US$100.0m (up 6.0% from 2Q 2022). Net income: US$11.9m (up 33% from 2Q 2022). Profit margin: 12% (up from 9.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany.
Recent Insider Transactions • May 10Independent Director recently sold €3.4m worth of stockOn the 8th of May, Thomas Oberdorf sold around 27k shares on-market at roughly €129 per share. This transaction amounted to 91% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €16m more than they bought in the last 12 months.
Board Change • Apr 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Cynthia Feldmann was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €120, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total returns to shareholders of 102% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €85.63 per share.
Reported Earnings • Mar 12Full year 2022 earnings released: EPS: US$5.53 (vs US$2.11 in FY 2021)Full year 2022 results: EPS: US$5.53 (up from US$2.11 in FY 2021). Revenue: US$353.8m (up 72% from FY 2021). Net income: US$41.8m (up 163% from FY 2021). Profit margin: 12% (up from 7.7% in FY 2021). Revenue is forecast to grow 4.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.